Brief: Crossject enters into partnering agreement with Sayre Therapeutics
14/09/2015 16:46
Sept 14 (Reuters) - Crossject SA ALCJ.PA :
* Crossject enters into partnering agreement with Sayre Therapeutics to commercialize ZENEO
Methotrexate in India
Source text for Eikon: ID:nHUG3L9g3m
Further company coverage: ALCJ.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))
Recent news on Crossject SA
See all newsBrief: Crossject Says Expects To File For EUA Early Next Year For Epilepsy Rescue Therapy Zepizure
Brief: Crossject Signs A Geographic Extension Of Zepizure Commercialization Agreement In Europe
Brief: Crossject FY Operating Income Up At EUR 12.82 Mln
Brief: Crossject Announces Contract Of Up To $155 Mln With BARDA
Brief: Crossject Engages Syneos Health For U.S. Commercial Launch Of Zepizure